[Treatment of anemia in patients with renal failure using erythropoietin obtained by genetic recombination].
In 5 haemodialyzed patients with end-stage renal failure an effect of human recombinant erythropoietin (r-huEpo) on haemoglobin, haematocrit and iron metabolism was studied. After 12 weeks of the treatment, a significant increase in haemoglobin and haematocrit but significant decrease in plasma ferritin were noted. During r-huEpo treatment, one patients presented clinical symptoms of increased blood coagulation whereas another patients an increase in blood pressure. r-huEpo did not influence leukocytes and platelets count as well as liver function tests. Our results suggest, that r-huEpo is highly effective and safe in the treatment of anaemia in patients with chronic uraemia. Iron metabolism, blood pressure and blood coagulation must be monitored during therapy with r-huEpo.
Wiecek
A
A
Kliniki Nefrologii Sl. AM w Katowicach.
Kokot
F
F
Grzeszczak
W
W
Klin
M
M
D000328:Adult; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D004906:Erythrocyte Count / Q000187:drug effects; D004921:Erythropoietin / Q000096:biosynthesis / Q000172:deficiency / Q000235:genetics / Q000627:therapeutic use*; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D011995:Recombination, Genetic
D006454:Hemoglobins; D004921:Erythropoietin
Leczenie niedokrwistości u chorych na niewydolność nerek za pomoca erytropoetyny uzyskanej przez rekombinacje genetyczna.